Lawyers specializing in stem cell technologies are handling a steady growth in patent work and, for the first time, vetting investment opportunities for private equity firms as philanthropists and states outside California step up funding for research in the area.
Already, private investments, such as New York Mayor Michael Bloomberg’s $100 million donation to Johns Hopkins University last year, have spurred an uptick in patent work. In recent months, some lawyers have advised private equity firms looking to invest in startups with stem cell technologies.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
